Nasdaq:US$9.56 (+0.50) | HKEX:HK$15.34 (+0.18) | AIM:£1.50 (+0.01)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors